Medical care and travel in China, coordinated for international patientsGet a personal plan
Get a quote

Rare & hard-to-treat diseases

Advanced / refractory cancer (clinical trials & novel therapy)

Hospitals in China recommended for Advanced / refractory cancer, with Fudan specialty rankings and sources. Related specialties: Oncology, Hematology.

Ask about this condition

General information only. It is not a diagnosis or a substitute for professional advice.

Last updated:

  • Related specialties: Oncology · Hematology
  • Also known as: CAR-T, solid tumor CAR-T, immunotherapy, cell therapy, clinical trial, refractory cancer

Recommended hospitals

Hospitals are listed in order of recommendation, based on the Fudan specialty reputation ranking and published sources. This is not medical advice.

  1. 1
    Cancer Hospital, Chinese Academy of Medical Sciences

    BeijingGrade 3A Public HospitalOncology #1International patient department

    No.1 in Fudan oncology specialty reputation ranking, National Cancer Center with large number of clinical trials on novel therapies and cellular immunotherapy for advanced/refractory tumors; Ranked #1 in the 2023 Fudan Oncology specialty reputation ranking

    Sources: rank.cn-healthcare.comsohu.com

  2. 2
    Sun Yat-sen University Cancer Center

    GuangzhouGrade 3A Public HospitalOncology #2International patient department

    No.2 in Fudan oncology specialty reputation ranking with characteristic technologies for liver and nasopharyngeal cancers and high volume of multicenter international clinical trials for advanced tumors; Ranked #2 in the 2023 Fudan Oncology specialty reputation ranking

    Sources: rank.cn-healthcare.comsohu.com

  3. 3
    Fudan University Shanghai Cancer Center

    ShanghaiGrade 3A Public HospitalOncology #3International patient department

    No.3 in Fudan oncology specialty reputation ranking, leads in precision oncology and immunotherapy clinical trials with capacity for international patients; Ranked #3 in the 2023 Fudan Oncology specialty reputation ranking

    Sources: rank.cn-healthcare.comsohu.com

  4. 4
    Peking University Cancer Hospital

    BeijingGrade 3A Public HospitalOncology #4

    No.4 in Fudan oncology specialty reputation ranking, active in clinical trials of immunotherapy and targeted novel therapies for advanced/refractory tumors with national key clinical specialty; Ranked #4 in the 2023 Fudan Oncology specialty reputation ranking

    Sources: rank.cn-healthcare.comsohu.com

  5. 5
    West China Hospital of Sichuan University

    ChengduGrade 3A Public HospitalOncology #8International patient department

    Leads in Fudan comprehensive hospital ranking, oncology department conducts large number of new drug clinical trials for advanced cancer as western regional clinical research hub; Ranked #8 in the 2023 Fudan Oncology specialty reputation ranking

    Sources: rank.cn-healthcare.comsohu.com

  6. 6
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    WuhanGrade 3A Public HospitalHematology #5International patient department

    Ranked #5 in the 2023 Fudan Hematology specialty reputation ranking

    Sources: rank.cn-healthcare.com

Other notable hospitals

Related news

View all
First Enrollment in Multicenter Clinical Trial of Domestic Dual-Arm Endoscopic Robot; Hospital Leads Full Chain from Prototype to Procedure

Rare & hard-to-treat diseases

First Enrollment in Multicenter Clinical Trial of Domestic Dual-Arm Endoscopic Robot; Hospital Leads Full Chain from Prototype to Procedure

The Digestive Center completed the first patient enrollment in a multicenter clinical study using the dual-arm endoscopic robot for gastrointestinal lesion treatment. This marks the domestic robot's transition from engineering R&D to clinical validation, advancing medicine-engineering integration.

Beijing Friendship Hospital, Capital Medical University

A Lifeline Across the Ocean: An American Patient with Advanced Cancer Travels from Los Angeles to Shenzhen for TreatmentVideo

OncologyInternational patient story

A Lifeline Across the Ocean: An American Patient with Advanced Cancer Travels from Los Angeles to Shenzhen for Treatment

Larry Black of Los Angeles (with his wife Jamie) had advanced gastroesophageal-junction adenocarcinoma with peritoneal metastasis that progressed through multiple lines of therapy; 99% of tumor cells were Claudin18.2 2+/3+. After China's NMPA approved the world's first solid-tumor CAR-T (satri-cel, Claudin18.2-targeted) in June 2026, the couple travelled to the International Medical Center of HKU-Shenzhen Hospital. Prof. Pan Hongming's team infused the CAR-T cells on 29 Sep 2026; after cytokine release syndrome was managed with tocilizumab, CA19-9 fell from 8,200 to 57.6 U/mL with marked tumor shrinkage and near-complete remission, and he was discharged.

The University of Hong Kong-Shenzhen Hospital (International Medical Center)

Across 10,000 km for a Chance at Life: Hangzhou Completes Its First Solid-Tumor CAR-T Treatment for an Overseas Chinese-American Gastric Cancer Patient

OncologyInternational patient story

Across 10,000 km for a Chance at Life: Hangzhou Completes Its First Solid-Tumor CAR-T Treatment for an Overseas Chinese-American Gastric Cancer Patient

The team of Zheng Yu at Sir Run Run Shaw Hospital used the world's first approved solid-tumor CAR-T (satri-cel, CLDN18.2-targeted) to treat a Chinese-American advanced gastric cancer patient whose multi-line treatment in the US had failed — Zhejiang's first such case.

Sir Run Run Shaw Hospital

World First: The Lancet Publishes Randomized Trial of Claudin18.2 CAR-T (satri-cel) in Gastric Cancer, Led by Peking University Cancer HospitalVideo

Oncology

World First: The Lancet Publishes Randomized Trial of Claudin18.2 CAR-T (satri-cel) in Gastric Cancer, Led by Peking University Cancer Hospital

CT041-ST-01 is the world's first randomized phase II trial of a solid-tumor CAR-T: in CLDN18.2-positive advanced gastric/GEJ cancer after at least two prior lines, satri-cel gave median PFS of 3.25 vs 1.77 months (HR 0.37) with manageable safety. The work supported the 2026 NMPA approval of the first solid-tumor CAR-T.

Peking University Cancer Hospital

World's First! Renji Hospital Academician Xia Qiang Team Publishes Nature Medicine Results on In Vivo Liver-Targeted Base Editing for Heterozygous Familial Hypercholesterolemia

Rare & hard-to-treat diseases

World's First! Renji Hospital Academician Xia Qiang Team Publishes Nature Medicine Results on In Vivo Liver-Targeted Base Editing for Heterozygous Familial Hypercholesterolemia

Academician Xia Qiang's team completed the world's first Phase I trial of liver-targeted in vivo base editing gene therapy for heterozygous familial hypercholesterolemia, achieving an average 52.3% LDL-C reduction with favorable safety. It offers a potential one-time treatment for genetic metabolic diseases.

Renji Hospital Shanghai Jiao Tong University School of Medicine

New Breakthrough in Tumor Radiotherapy! South China's First Proton Therapy Equipment Installed at Southern Hospital Zengcheng Campus

Infectious disease

New Breakthrough in Tumor Radiotherapy! South China's First Proton Therapy Equipment Installed at Southern Hospital Zengcheng Campus

Southern Hospital's Zengcheng Campus successfully installed South China's first integrated proton radiotherapy system cyclotron accelerator, marking a new era in precise tumor radiotherapy. Proton therapy precisely targets tumors while significantly reducing damage to normal tissues and is suitable for pediatric tumors and various solid tumors.

Nanfang Hospital, Southern Medical University

Advisor onlineAsk now